Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN.DL)

CAPS Rating: No stars

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.


Player Avatar glennwhiteside (23.13) Submitted: 10/20/2010 12:20:30 PM : Outperform Start Price: $11.04 AMLN.DL Score: +8.90


Report this Post 2 Replies
Member Avatar tennhogg (70.12) Submitted: 10/21/2010 8:23:16 PM
Recs: 0

glennwhiteside, You are right! I had 100 shares of Amylin. So? I bought 100 more the day it dropped.
It still has a big advantage over competition ( a moat I think in its once a week injection) Eli Lily has the European market which could approve Bydureon much sooner than the U.S.

Member Avatar glennwhiteside (23.13) Submitted: 10/28/2010 10:29:52 PM
Recs: 0

sometimes I am right! not as often as I'd like though...

Featured Broker Partners